drugset / Trial / NCT01963208

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208

Phase 3 Completed 405 enrolled Marinus Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).

Timeline

Start
2013-10
Primary completion
2016-05
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule 1200 mg
Subject Ganaxolone Small molecule 1800 mg